|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
Q3 FY2016
As of Sep 30, 2016
|
Q2 FY2016
As of Jun 30, 2016
|
Q1 FY2016
As of Mar 31, 2016
|
Q4 FY2015
As of Dec 31, 2015
|
Q3 FY2015
As of Sep 30, 2015
|
Q2 FY2015
As of Jun 30, 2015
|
Q1 FY2015
As of Mar 31, 2015
|
Q4 FY2014
As of Dec 31, 2014
|
Q3 FY2014
As of Sep 30, 2014
|
Q2 FY2014
As of Jun 30, 2014
|
Q1 FY2014
As of Mar 31, 2014
|
Q4 FY2013
As of Dec 31, 2013
|
Q3 FY2013
As of Sep 30, 2013
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Fixed maturity investments trading, at fair value (amortized cost: 2018—$5,651,953; 2017—$5,876,261) | ||||||||||||||||||||
| Short-term investments trading, at fair value (amortized cost: 2018—$3,728,930; 2017—$3,381,714) | ||||||||||||||||||||
| Other investments, at fair value (cost: 2018—$341,883; 2017—$330,416) | ||||||||||||||||||||
| Investments in investment affiliates, equity method (cost: 2018—$72,135; 2017—$61,944) | ||||||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Total investments and cash | ||||||||||||||||||||
| Investment in operating affiliate, equity method (cost: 2016—$nil; 2015—$392) | ||||||||||||||||||||
| Premiums receivable | ||||||||||||||||||||
| Deferred acquisition costs | ||||||||||||||||||||
| Prepaid reinsurance premiums | ||||||||||||||||||||
| Securities lending collateral | ||||||||||||||||||||
| Loss reserves recoverable | ||||||||||||||||||||
| Paid losses recoverable | ||||||||||||||||||||
| Income taxes recoverable | ||||||||||||||||||||
| Deferred tax asset | ||||||||||||||||||||
| Receivable for investments sold | ||||||||||||||||||||
| Intangible assets | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Accrued investment income | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Reserve for losses and loss expenses | ||||||||||||||||||||
| Unearned premiums | ||||||||||||||||||||
| Reinsurance balances payable | ||||||||||||||||||||
| Securities lending payable | ||||||||||||||||||||
| Deferred tax liability | ||||||||||||||||||||
| Payable for investments purchased | ||||||||||||||||||||
| Accounts payable and accrued expenses | ||||||||||||||||||||
| Variable Interest Entity, Consolidated, Carrying Amount, Notes Payable | ||||||||||||||||||||
| Notes payable to AlphaCat investors | ||||||||||||||||||||
| Senior notes payable | ||||||||||||||||||||
| Debentures payable | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Redeemable noncontrolling interests | ||||||||||||||||||||
| Shareholders' equity | ||||||||||||||||||||
| Preferred shares (Issued and Outstanding: 2018—16,000; 2017—16,000) | ||||||||||||||||||||
| Common shares (Issued: 2018—163,186,889; 2017—161,994,491; Outstanding: 2018—80,511,948; 2017—79,319,550) | ||||||||||||||||||||
| Treasury shares (2018—82,674,941; 2017—82,674,941) | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Accumulated other comprehensive income (loss) | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Total shareholders' equity available to Validus | ||||||||||||||||||||
| Noncontrolling interests | ||||||||||||||||||||
| Total shareholders' equity | ||||||||||||||||||||
| Total liabilities, noncontrolling interests and shareholders’ equity | ||||||||||||||||||||
Loading...
